Spence Jessica, Devereaux P J, Lee Shun-Fu, D'Aragon Frédérick, Avidan Michael S, Whitlock Richard P, Mazer C David, Rousseau-Saine Nicolas, Rajamohan Raja Ramaswamy, Pryor Kane O, Klein Rael, Tan Edmund, Cameron Matthew J, Di Sante Emily, DeBorba Erin, Mustard Mary E, Couture Etienne J, Zamper Raffael Pereira Cezar, Law Michael W Y, Djaiani George, Saha Tarit, Choi Stephen, Hedlin Peter, Pikaluk D Ryan, Lam Wing, Deschamps Alain, Ramasundarahettige Chinthanie F, Vincent Jessica, McIntyre William F, Oczkowski Simon J W, Dulong Braden J, Beaver Christopher, Kloppenburg Shelley A, Lamy Andre, Jacobsohn Eric, Belley-Côté Emilie P
Population Health Research Institute, Hamilton, Ontario, Canada.
Department of Anesthesia and Critical Care, McMaster University, Hamilton, Ontario, Canada.
JAMA Surg. 2025 Mar 1;160(3):286-294. doi: 10.1001/jamasurg.2024.6602.
Delirium is common after cardiac surgery and associated with adverse outcomes. Intraoperative benzodiazepines may increase postoperative delirium but restricting intraoperative benzodiazepines has not yet been evaluated in a randomized trial.
To determine whether an institutional policy of restricted intraoperative benzodiazepine administration reduced the incidence of postoperative delirium.
DESIGN, SETTING, AND PARTICIPANTS: This pragmatic, multiperiod, patient- and assessor-blinded, cluster randomized crossover trial took place at 20 North American cardiac surgical centers. All adults undergoing open cardiac surgery at participating centers during the trial period were included through a waiver of individual patient consent between November 2019 and December 2022.
Institutional policies of restrictive vs liberal intraoperative benzodiazepine administration were compared. Hospitals (clusters) were randomized to cross between the restricted and liberal benzodiazepine policies 12 to 18 times over 4-week periods.
The primary outcome was the incidence of delirium within 72 hours of surgery as detected in routine clinical care, using either the Confusion Assessment Method-Intensive Care Unit or the Intensive Care Delirium Screening Checklist. Intraoperative awareness by patient report was assessed as an adverse event.
During the trial, 19 768 patients (mean [SD] age, 65 [12] years; 14 528 [73.5%] male) underwent cardiac surgery, 9827 during restricted benzodiazepine periods and 9941 during liberal benzodiazepine periods. During restricted periods, clinicians adhered to assigned policy in 8928 patients (90.9%), compared to 9268 patients (93.2%) during liberal periods. Delirium occurred in 1373 patients (14.0%) during restricted periods and 1485 (14.9%) during liberal periods (adjusted odds ratio [aOR], 0.92; 95% CI, 0.84-1.01; P = .07). No patient spontaneously reported intraoperative awareness.
In intention-to-treat analyses, restricting benzodiazepines during cardiac surgery did not reduce delirium incidence but was also not associated with an increase in the incidence of patient-reported intraoperative awareness. Given that smaller effect sizes cannot be ruled out, restriction of benzodiazepines during cardiac surgery may be considered. Research is required to determine whether restricting intraoperative benzodiazepines at the patient level can reduce the incidence of postoperative delirium.
ClinicalTrials.gov Identifier: NCT03928236.
谵妄在心脏手术后很常见,并与不良后果相关。术中使用苯二氮䓬类药物可能会增加术后谵妄的发生率,但在随机试验中尚未对限制术中使用苯二氮䓬类药物进行评估。
确定限制术中使用苯二氮䓬类药物的机构政策是否能降低术后谵妄的发生率。
设计、设置和参与者:这项务实、多阶段、患者和评估者双盲的整群随机交叉试验在20个北美心脏外科中心进行。在2019年11月至2022年12月期间,通过免除个体患者同意书,纳入了试验期间在参与中心接受心脏直视手术的所有成年人。
比较了限制与宽松的术中苯二氮䓬类药物使用机构政策。医院(整群)被随机分配在4周的时间段内交叉采用限制和宽松的苯二氮䓬类药物政策12至18次。
主要结局是在常规临床护理中检测到的术后72小时内谵妄的发生率,使用重症监护病房意识模糊评估法或重症监护谵妄筛查清单。通过患者报告评估术中知晓情况作为不良事件。
在试验期间,19768例患者(平均[标准差]年龄,65[12]岁;14528[73.5%]为男性)接受了心脏手术,9827例在限制使用苯二氮䓬类药物期间,9941例在宽松使用苯二氮䓬类药物期间。在限制期,8928例患者(90.9%)的临床医生遵守了指定政策,而在宽松期为9268例患者(93.2%)。限制期有1373例患者(14.0%)发生谵妄,宽松期有1485例(14.9%)(调整后的优势比[aOR],0.92;95%置信区间,0.84 - 1.01;P = 0.07)。没有患者自发报告术中知晓情况。
在意向性分析中,心脏手术期间限制使用苯二氮䓬类药物并未降低谵妄发生率,但也未与患者报告的术中知晓发生率增加相关。鉴于不能排除较小的效应量,可考虑在心脏手术期间限制使用苯二氮䓬类药物。需要进行研究以确定在患者层面限制术中使用苯二氮䓬类药物是否能降低术后谵妄的发生率。
ClinicalTrials.gov标识符:NCT03928236。